APRE - Aprea Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Aprea Therapeutics, Inc.

535 Boylston Street
Boston, MA 02116
United States

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Christian S. SchadePres, CEO & Director593.28kN/A1961
Dr. Gregory A. Korbel Ph.D.VP of Bus. Devel.276.45kN/A1976
Mr. Scott M. CoianteSr. VP & CFON/AN/A1967
Dr. Lars B. AbrahmsénSr. VP & Chief Scientific OfficerN/AN/A1957
Dr. Eyal C. Attar M.D.Sr. VP & Chief Medical OfficerN/AN/A1970
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aprea Therapeutics, Inc., a biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its lead product candidate is APR-246, a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes and acute myeloid leukemia. The company was founded in 2006 and is headquartered in Boston, Massachusetts.

Corporate Governance

Aprea Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.